The UMR INSERM U1122 IGE-PCV has set-up two shared plateforms

 

  • A Biological Ressources Center (BRC) for storing and quality control of our and collaborative biological ressources;

 

  • And a Biostatistics / Bionformatics platform for 'big data' storage and analytical and methodological support on standardized and ad hoc epidemiological procedures

 

The shared ressouces of this platforms allow us to adapt to national and international standards of collaborations.

Postdocral fellowship

Phone:
Adress:

PhD Student in 3rd year - Developing phenome-wide association studies (PheWAS) within an integrative approach of the etiologic study of cardiovascular diseases and related risk factors

Phone:
Email:
Adress: UMR INSERM U1122 IGE-PCV, Université de Lorraine, 30 rue Lionnois, 54000 Nancy

Head of Replication Studies

Phone:
Adress: UMR INSERM U1122 IGE-PCV, Université de Lorraine, 30 rue Lionnois, 54000 Nancy

PhD Student in 3rd year and Hospital staff member

Phone:
Adress: UMR INSERM U1122 IGE-PCV, Université de Lorraine, 30 rue Lionnois, 54000 Nancy

Assistant Professor

Phone: 00 33 3 83 68 21 97
Adress: UMR INSERM U1122 IGE-PCV, Université de Lorraine, 30 rue Lionnois, 54000 Nancy

INSERM UMR U1122; IGE-PCV

Université de Lorraine - Présidence site Lionnois

22-30 rue Lionnois
54000 Nancy

The Research Unit UMR INSERM U1122 IGE-PCV is dedicated to the study of the genetic and environmental components influencing cardiovascular pathophysiology. In order to identify early cardiovascular markers, the unit developed an approach based on apparently healthy familial populations and on genotype-intermediate phenotypes investigations from a transversal and/or longitudinal point of view. This innovative methodology integrates genomics, transcriptomics and proteomics (systems biology) in order to identify functional polymorphisms useful in prevention and prediction. It implies a multidisciplinary strategy based on an internal collaborative network gathering epidemiologists, biochemists, molecular biologists, geneticists, biostatisticians and clinicians; and on an external collaborative network gathering large International Consortia. This strategy allowed the unit to identify new biomarkers involved in blood pressure, lipids, cellular adhesion, inflammation metabolic pathways, and anthropometric traits variability.

The unit constantly adapts to recent methodologies, especially regarding high throughput genotyping data exploitation. Since 2007, genome-wide association studies (GWAS) in paediatric populations completing the initial candidate gene approach have been developed in partnership with Research Teams owning replication populations or within International Consortia dedicated to large genome-wide studies. And more recently, using a phenome-wide approach, next generation sequencing and epigenetics (EWAS) have been integrated to the team's strategy. Analytical and genotyping technologies advances are paired with biostatistics/bioinformatics methodologies and the researchers of the unit are actively engaged in continuous update of their skills in these domains.

January 1, 2013 is a milestone for the team which obtained the UMR INSERM label in the ‘Université de Lorraine’, after 14 years of innovative researches and national and international collaborations, which allowed going further in the understanding of the cardiovascular pathophysiology.

Another important fact is the creation, in 2002, of a Biological Ressources Center (BRC), part of the National Biobank network with the ‘Infrastructures Coordination in Life Sciences' or ‘Coordination des Infrastructures en Sciences du Vivant’ (GIS) and of the European ‘Biobanking and Biomolecular Resources Research Infrastructure’ (BBMRI), 7th PCRD. This BRC is an IBISA platform involved in the forthcoming investment project ‘BIOBANQUES’.

In 2009, researchers of the unit participated in the creation of the ‘European Society of Predictive Medicine’ (EUSPM) and in 2011, created the ‘European Society of Pharmacogenomics and Theranostics’ (ESPT).

Finally, since 2002, the unit organises every two years a conference in pharmacogenomics in Santorini, Greece.

1. Plateform " -omics "

In 2014, in order to answer to the methodological and technological needs of « -omics » data analyses (especially those of NGS) and for being able to guaranty the rapidity and performance required by the large-scale analyses done by our team inside the Consortia, we linked to the BRC IGE-PCV a mutualised Biostatistics/Bioinformatics platform for "-omics" analyses.

2. International collaborations

We set up partnerships with teams and cooperation networks giving us access to internationally recognised cohorts:

  • The Framingham cohort « National Heart Lung and Blood Institute » -NHLBI- (Framingham, Boston, United States of America), S. Seshadri, on VEGF, since 2010;
  • The LifeLines cohort (The Netherlands), B. Alizadeh, on VEGF and inflammation molecules, since 2013.

3. Consortia

We integrated International consortia having the required experience and populations for replications aiming at very extensive "-omics" studies:

  • The  « MAGIC (Meta-Analyses of Glucose and Insulin-related traits) Consortium », since 2008;
  • The "CHARGE - Inflammation (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium", since 2013. We participate in 3 projects ('TNF-a Meta-GWAS', 'IL6 Meta GWAS ' and 'CRP Meta-GWAS');
  • The "Social Science Genetics Association Consortium for Reproductive Behavior", University of Groningen, Jornt Mandemakers and Nicola Barban, since 2013.
  • The "Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (NCD Risk Factor Collaboration - NCD-RisC)", since 2014.

4. Le Consortium VEGF

We have created in 2015, the VEGF "Vascular endothelial growth factor European Genomic Federation" Consortium gathered, under the leadership of Sofia Siest, Director of the Unit, 14 partnerships issued from 7 different countries (including US) with a scientific expertise worldwide recognised in divers domaines but complementary to VEGF.

Publications number and Mean IF

A. All Publications, Mean IF & Publications number

B. Original Publications, Mean IF & Publications number

 

Despites an advanced knowledge of the human genome, a limited percentage of the genetic variability of cardiovascular risk factors has been elucidated so far and a restricted number of SNPs have been proposed for cardiovascular prevention. Furthermore, given the limited efficacy of cardiovascular prevention strategies based on the diminution of classical risk factors, it is urgent to identify new risk markers among which genetic factors represent a major target. However, the search for cardiovascular predisposition factors needs a global and complex approach including genotyping analyses and the assessment of environmental factors and pertinent intermediate phenotypes. The classic candidate gene approach, although essential, has obvious limitations. In particular, it was mostly funded on a strictly clinic approach of the phenotype (i.e. the disease). Yet the clinic homogeneity of a multifactorial pathology has no reason to reflect pathophysiology homogeneity or genetic homogeneity. Furthermore, 1) the biologic effect of genes, of their products and of their variations in healthy subjects and in physiologic conditions are still unknown; 2) most studies are focused on a particular metabolic cycle or on a gene / molecule independently to others.

This led us to propose a complementary ‘deductive’ approach simultaneously to case-control studies. This approach starts from the gene to the disease and consists in focusing on metabolic pathways, and consequently on coherent ensemble of genes and intermediate phenotypes whose variability could influence the predisposition to the disease. Two types of studies are realised. First, a study on healthy individuals which would allow, without the influence of the pathology and /or the treatment, to better understand the genes regulation mechanisms and secondly, case-control studies which would allow, after the application of the first step conclusions, to propose pertinent markers for cardiovascular prevention and prediction.

The general objective of our Research Programme is thus to advance the knowledge of mechanisms involved in the cardiovascular pathologies using an integrative approach, from the genotype to the phenotype through the biological phenotype and taking into account environmental factors. More particularly, we are focused on genes coding for adhesion and inflammation molecules; without neglecting metabolic pathways having an established effect on atherosclerosis: lipid metabolism, blood pressure regulation, coagulation, homocystein and antioxidant systems.

The website www.u1122.inserm.fr/en has been released by the research unit Inserm 1122,

Faculté de Pharmacie
30 rue Lionnois
54000 Nancy
Téléphone : 06 07 60 25 69

Directrice de la publication : Sophie Visvikis-Siest, directrice de l'unité 1122.
Webmestre : Ndeye Coumba Ndiaye (contacter le webmestre)
Hébergement : agence Tiz

L'utilisation du site est réservée à un usage personnel. L'accès au site peut être interrompu à tout moment, sans préavis, notamment en cas de force majeure, de maintenance ou si son éditeur décide de suspendre ou d'arrêter la fourniture de ce service.
L'éditeur s'efforce d'assurer au mieux de ses possibilités, l'exactitude et la mise à jour des informations diffusées, au moment de leur mise en ligne sur le site. Cependant, il ne garantit en aucune façon l'exactitude, la précision ou l'exhaustivité des informations mises à disposition. Les informations présentes sur le site sont non-contractuelles et peuvent être modifiées à tout moment.
Le site est régi par la loi française. Les utilisateurs étrangers acceptent formellement l'application de la loi française en visitant ce site et en utilisant tout ou partie des fonctionnalités du site.

Propriété intellectuelle
Les contenus qui apparaissent ou sont disponibles sur le site sont protégés par le droit de la propriété intellectuelle et sont la propriété exclusive de l'éditeur. A ce titre, vous vous engagez à ne pas copier, traduire, reproduire, vendre, publier, exploiter et diffuser des contenus du site protégés par le droit de la propriété intellectuelle, sans autorisation préalable et écrite de l'éditeur.

Vie privée
L'éditeur s'engage à ne pas divulguer à des tiers les informations que l'internaute lui communique. Celles-ci sont confidentielles et ne seront utilisées que pour les besoins du service.Le site répond à la réglementation relative à l'informatique, aux fichiers et aux libertés telle que définie par la loi n°78-17, modifiée. L'internaute dispose, pour ce qui concerne ses données personnelles collectées lors de sa visite sur le site, d'un droit d'accès, de modification, de rectification et de suppression des données conformément à la loi française. Ces droits peuvent être exercés auprès de l'éditeur : unité 1122 dot l'adresse figure plus haut

Liens
Le site peut contenir des liens vers des sites de partenaires ou de tiers. L'Inserm ne disposant d'aucun moyen pour contrôler ces sites n'offre aucune garantie quant au respect par ces sites des lois et règlement en vigueur.

Alerte démarchage
L'éditeur ne vend aucun emplacement publicitaire dans sa publication. Toute démarche en ce sens, est faite en fraude des droits de l'éditeur.

 

Faculté de Pharmacie
30 rue Lionnois
54000 Nancy
Telephone: 06 07 60 25 69

Publishing director: Sophie Visvikis-Siest, Director, Unit 1122.
Webmaster: Ndeye Coumba Ndiaye (contact the webmaster)
Hosting: agence Tiz

Use of this site is reserved for personal purposes. Access to the site may be terminated at any time without notice, especially for reasons of force majeure or maintenance, or if the publisher decides to suspend or terminate the provision of this service. 

The publisher undertakes to ensure to the best of its abilities the accuracy and up-to-date nature of the information provided at the time of publication on the website. However, it does not guarantee the accuracy, accuracy or completeness of the information provided. The information on this site is non-contractual and may be changed at any time. 

This site is governed by French law. Foreign users formally accept the application of French law by visiting this site and using all or part of the site's features. 

Intellectual property 
The contents which appear or are available on the site are protected by copyright and intellectual property and are the exclusive property of the publisher. As such, you undertake not to copy, translate, reproduce, sell, publish, exploit or disseminate the site contents protected by intellectual property rights without prior written permission from the publisher. 

Private data 
The publisher undertakes not to disclose information communicated by internet users to third parties. These are confidential and will only be used for the purposes of the service. The site complies the regulations relating to data, files and freedoms as defined by Law No. 78-17, as amended. In respect of personal data collected during the site visit, the internet user has a right to access, modify, rectify and delete data in accordance with French law. These rights can be exercised by contacting the publisher at Unit 1122 at the address given above 

Links 
The site may contain links to websites operated by partners or third parties. Inserm has no way to control these sites and offers no warranty for these sites in terms of compliance with the laws and regulations in force. 

Canvassing alert 
The publisher does not sell advertising space in the publication. Any initiative for this purpose constitutes fraud and in contravention of the publisher’s rights.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam diam purus, bibendum tincidunt felis a, venenatis hendrerit quam. Morbi et imperdiet sapien, placerat consectetur tortor. Aenean condimentum molestie dignissim. Pellentesque eu gravida quam, in lacinia dolor. Cras sit amet dui sapien. Curabitur nec leo erat. Duis molestie venenatis tincidunt. Mauris vestibulum porttitor sagittis. Mauris aliquam risus consequat purus molestie, quis tincidunt nunc tincidunt. Etiam luctus tortor dui, non sodales leo mollis at. Nullam a pretium ipsum. Donec sagittis, ante in mollis fermentum, urna libero auctor odio, et mattis tellus erat nec felis. Nulla non nisi odio. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. In adipiscing sapien vitae dui dignissim, et interdum turpis tincidunt. Ut consectetur sed magna non aliquam.

Morbi at tortor in massa euismod sagittis quis non dolor. Nullam id aliquet est. In hac habitasse platea dictumst. In hac habitasse platea dictumst. Phasellus iaculis massa ac justo lacinia mollis molestie a mi. Fusce tincidunt vel nunc vel fringilla. Sed ac semper mi, non feugiat erat. Suspendisse elementum odio vel odio facilisis, sed lobortis nisi porttitor. Aenean eu enim lectus. Duis at tincidunt eros, eget dignissim arcu. Aenean elementum enim vel tristique lobortis. Cras a elit feugiat, ultricies tortor non, congue erat. Duis a scelerisque lacus. Integer id nulla enim. Integer id vulputate odio. Integer lobortis purus nisi, sed euismod est volutpat ac.

Quisque sodales purus justo, id egestas tortor luctus sed. Maecenas ultrices ipsum et ante iaculis, sed fringilla mi pretium. Praesent at egestas mi, non pretium augue. Curabitur eget bibendum diam, id porttitor mauris. Donec nec condimentum elit. Nunc mollis auctor elit sit amet consequat. Aenean imperdiet consectetur consequat. Morbi tempus eleifend lacus quis dictum. Etiam vitae augue at nunc dignissim egestas. Fusce tristique sem sit amet placerat dapibus. Fusce rutrum fermentum urna pulvinar imperdiet. Fusce ac turpis eget leo sodales sodales id ac purus. Sed eu laoreet metus, a iaculis odio.

Quisque pellentesque ac dolor ac placerat. Maecenas bibendum metus ut lacinia blandit. Fusce eget enim non nibh varius ullamcorper. Vestibulum laoreet dui vitae sem condimentum, vitae accumsan metus ultricies. Cras massa erat, sagittis et venenatis sed, fermentum sit amet metus. Mauris consequat lorem non enim feugiat luctus. Proin consequat sem purus, sit amet aliquet lectus vulputate non. Phasellus ut ipsum laoreet, aliquet purus ac, bibendum ante. Ut at gravida neque. Praesent pretium sem hendrerit tellus congue facilisis. Duis in dignissim nulla. Cras laoreet semper velit vel venenatis. Nulla quis justo velit. Quisque eu arcu in tellus varius fermentum non a metus.

Nullam in lectus vitae enim posuere porta. Aliquam ac pharetra ipsum. Nunc bibendum tortor eu consectetur blandit. Suspendisse quis nisi iaculis libero ullamcorper aliquet eget laoreet urna. Maecenas pretium adipiscing nisl, sit amet euismod metus dignissim quis. Nunc ornare, quam vitae faucibus adipiscing, augue dui accumsan odio, non cursus nunc nunc sit amet ipsum. Etiam ut dolor nisl. Integer sodales augue ullamcorper accumsan ullamcorper. Integer sed nibh pellentesque, dignissim dui sed, varius orci. Praesent in porttitor nulla. Nunc id orci urna.